Identify high-quality drug leads and optimize clinical candidates using DNA-encoded library data and Chemomics to reduce risk in biotech and pharma discovery.
Proxima
Design programmable protein interactions and discover next-generation proximity-based medicines using an integrated AI platform for biopharmaceutical research.
Paid only
Price not published
About Proxima
Proxima is an integrated discovery platform dedicated to unlocking the potential of proximity-based medicines by making protein interactions programmable. The platform focuses on three core modalities: inducers, modulators, and blockers. By decoding the complex interfaces of life, Proxima aims to enable a new chapter in medicine where biological interactions can be precisely engineered for therapeutic purposes. The company's mission is centered on the proximity modulator modality, a sophisticated approach to drug discovery that moves beyond traditional inhibition to active manipulation of protein relationships. The technology underlying Proxima combines data generation with advanced generative AI modeling to solve scientific challenges in drug discovery. The platform utilizes phase-shifting technologies to advance the design of biomolecular complexes and protein structures. Proxima is actively involved in the development and promotion of generative models such as Proteina, a flow-based protein backbone generator, and Boltz-1, an open-source model for 3D structure prediction. This focus on high-fidelity data generation allows the platform to predict and design molecular interactions with a level of precision that traditional methods often lack. This platform is primarily designed for biopharmaceutical companies, research institutions, and biotech startups looking to accelerate their drug discovery pipelines. It is particularly valuable for teams working on complex diseases that require more than simple blockers, specifically those targeting proximity-based therapeutic mechanisms like RIPTAC medicines. With strategic alliances involving industry leaders such as Bristol Myers Squibb, Johnson & Johnson, and Blueprint Medicines, the platform has proven its utility in high-stakes pharmaceutical research and development environments. What sets Proxima apart is its unique combination of proprietary discovery tools and a deep commitment to the broader AI research community. Unlike many closed-door biotech firms, Proxima hosts lecture series featuring researchers from NVIDIA and Microsoft Research, contributing to the democratization of biomolecular interaction modeling. Furthermore, the company is backed by significant investment from DCVC and NVIDIA, signaling strong industry confidence in their AI-driven approach to creating programmable medicine.
Proxima pros & cons
Pros
- Strategic partnerships with major pharmaceutical leaders like BMS and Johnson & Johnson.
- Significant financial backing from technology giants including NVIDIA.
- Utilizes cutting-edge generative AI models for high-fidelity protein structure prediction.
- Specialized focus on programmable proximity-based therapeutics, a novel frontier in medicine.
- Active contributor to the scientific community through open-source modeling and research lectures.
Cons
- Services are primarily targeted at large-scale enterprise partnerships rather than individual researchers.
- The core proprietary platform details and documentation are not publicly accessible without direct contact.
Proxima use cases
- Biopharmaceutical companies can use the platform to discover and design next-generation RIPTAC medicines through programmable protein interactions.
- Computational biology teams can leverage Proxima's AI-driven data generation to model complex biomolecular complexes more accurately.
- Biotech startups can partner with Proxima to access advanced phase-shifting technologies for proximity-based drug discovery.
Proxima features
- proximity modulator modality
- generative ai modeling
- protein structural ensemble emulation
- biomolecular interaction prediction
- blocker design
- modulator design
- inducer design
- integrated discovery platform
Proxima pricing
Is Proxima free? No, Proxima doesn't offer a free plan.
Enterprise Partnership
Price varies
- Custom drug discovery collaboration
- Access to proximity modulator platform
- Strategic research support
- Inducer design services
- Modulator design services
- Blocker design services
- Advanced data generation
Proxima FAQs
What is the primary focus of Proxima's discovery platform?
Proxima focuses on making protein interactions programmable to unlock proximity-based medicines. They specialize in creating three specific types of modalities: inducers, modulators, and blockers.
Which pharmaceutical companies has Proxima collaborated with?
The company has established strategic collaborations with several industry leaders, including Bristol Myers Squibb (BMS), Johnson & Johnson, and Blueprint Medicines. They also recently forged an alliance with Halda Therapeutics.
Does Proxima provide any open-source tools or research?
Yes, Proxima is involved in the development of open-source models like Boltz-1 for biomolecular interaction modeling. They also maintain a GitHub repository and host a lecture series on generative AI in drug discovery.
What kind of AI models does Proxima utilize in its platform?
Proxima utilizes generative AI models, including flow-based protein structure models like Proteina and structural ensemble emulators like BioEmu. These models are designed to rapidly emulate protein equilibrium and thermodynamic properties.
Ratings & reviews
No reviews yet. Be the first to share how Proxima worked for you.
Alternatives to Proxima
View all alternatives
Uncover new therapeutic insights and accelerate drug discovery with AI-driven life science intelligence designed for researchers and pharmaceutical teams.
Discover causal AI and digital twin solutions for drug discovery and disease biology research to accelerate modern biopharmaceutical therapeutics.
Accelerate biopharma R&D and drug discovery with agentic AI platforms, generative multi-omics pipelines, and computational chemistry workflows.
Accelerate small molecule drug discovery and tackle hard-to-drug targets using a clinical-stage AI platform designed for biotech and pharmaceutical researchers.
Identify new therapeutic indications for existing compounds using an AI-powered systems biology platform to reduce R&D costs and accelerate time-to-market.
AI-driven platform that accelerates the discovery of treatments for rare diseases.
Accelerate ALS drug discovery and target identification using deep generative models and multi-omics data analysis to find novel therapeutics for patients.
Accelerate drug discovery and clinical workflows with PhD-level AI systems designed specifically for biotech, pharma, and healthcare innovation.
Sponsored tools
Test your knowledge in live multiplayer Jeopardy-style trivia battles with AI-assisted grading that recognizes correct answers even with spelling mistakes.
Connect with engaged niche audiences or monetize your subscriber base through an automated marketplace featuring verified metrics and secure Stripe payments.
Track brand citations and mentions across Google AI Mode, ChatGPT, Claude, and more. Discover top-cited sources and queries with zero signup required.
Monitor brand citations and prompt visibility across Google AI Overviews, ChatGPT, Perplexity, Claude, and Gemini with free 30-day answer engine reports.
Generate cinematic videos with synchronized audio and multi-modal references. Empower creators and marketers to direct consistent characters, action, and sound.